Target Organ Damage in Hypertension: Pathophysiology and Implications for Drug Therapy

Author(s): Sunil K. Nadar, Muzahir H. Tayebjee, Franz Messerli, Gregory Y.H. Lip

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 13 , 2006

Become EABM
Become Reviewer
Call for Editor


Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.

Keywords: platelet activation, endothelial activation, target organ damage, Hypertension

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [1581 - 1592]
Pages: 12
DOI: 10.2174/138161206776843368
Price: $65

Article Metrics

PDF: 28